This grand round has already taken place.
this discussion will cover DOAC , clinical practice guidelines, risks, benefits and effectiveness of reversal agents and PCC
Dates and Times
Start: 2/5/2020 12:00 PM
End: 2/5/2020 1:00 PM
1.Recognize apixaban (Eliquis®), betrixaban (Bevyxxa®), dabigatran
(Pradaxa®), edoxaban (Savaysa®), and rivaroxaban (Xarelto®) as
2.Be aware of practice guidelines for reversal of DOACs and management of bleeding events
3.Describe risks, benefits and cost effectiveness of antidotes and prothrombin complex concentrates
Pathology level 2 conference room
100 Nicolls rd
university hospital room 749
Stony Brook, NY 11794
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.